01—Abstract
Summary
Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on January 8, 2024, providing preliminary, unaudited financial updates for the fiscal year ended December 31, 2023, during its presentation at the J.P.
Morgan Healthcare Conference. The company announced approximately $6.7 billiona in product sales for the full year, primarily driven by its COVID-19 vaccine. This figure includes an estimated $0.6 billion in deferred revenue related to its GAVI collaboration.
Furthermore, Moderna indicated a strong liquidity position, with cash, cash equivalents, and marketable securities expected to exceed $13 billionb as of December 31, 2023. Investors should note that this information is preliminary and subject to audit, and the full audited financial statements may present changes. The filing serves as an early outlook on the company's performance and financial health heading into the new fiscal year.
02—Key points
Key Highlights
- Preliminary 2023 product sales estimated at approximately $6.7 billion, primarily from COVID-19 vaccine.
- Includes approximately $0.6 billion in recognized deferred revenue from GAVI collaboration for 2023.
- Projected cash, cash equivalents, and marketable securities to exceed $13 billion as of December 31, 2023.
- Information provided is unaudited and preliminary.
- Full audited financial statements for fiscal year 2023 are still ongoing.
- The update was provided in connection with the 42nd Annual J.P. Morgan Healthcare Conference.
03—Questions
Frequently Asked Questions
What were Moderna's total product sales for 2023?
Moderna's preliminary and unaudited product sales for the fiscal year ended December 31, 2023, are estimated to be approximately $6.7 billion, driven mainly by its COVID-19 vaccine.
How much deferred revenue was recognized in 2023?
The company recognized approximately $0.6 billion of deferred revenue in 2023, related to its efforts with GAVI, The Vaccine Alliance.
What is Moderna's projected cash position at the end of 2023?
Moderna's current expectation is that its cash, cash equivalents, and marketable securities will be in excess of $13 billion as of December 31, 2023.
Is the financial information provided in this filing audited?
No, the financial information provided in this 8-K filing is preliminary and unaudited. The audit of the company's financial statements for the year ended December 31, 2023, is still ongoing and could lead to changes in these figures.
04—Continue